William Oh/Linkedin
Nov 26, 2023, 11:50
William Oh: The results of the largest cohort of over 17k men of European ancestry who underwent exome sequencing with aggressive prostate cancer
William Oh, Chief Medical Officer at Prostate Cancer Foundation, posted on LinkedIn:
“Germline genetic testing is important in defining prostate cancer risk, but panel tests may miss important pathogenic variants. In this largest cohort of over 17k men of European ancestry who underwent exome sequencing, Burcu Darst, Chris Haiman and colleagues identified BRCA2, ATM and NBN as strongly associated with aggressive prostate cancer, as well as nominal evidence for rare variants in MSH2, XRCC2 and MRE11A, the latter 2 often not in panels. Why test? It can affect patient management and thus outcomes, as well as family testing.”
Read more here.
Source: William Oh/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 10:51
Dec 22, 2024, 10:44
Dec 22, 2024, 09:04